



1/19

FIG. 1




2/19

FIG. 2A




61/9

FIG. 2B




4/19

FIG. 3




5/19

FIG. 4




6/19

FIG. 5




7/19

FIG. 6A




61/8

FIG. 6B




9/19

FIG. 7
Isoliquiritigenin



10/19


FIG. 8
Cell viability (MTT) curves for Wogonin treatment of LNCaP and DU145



11/19

FIG. 9

Cell viability (MTT) curves for Isoliquiritigenin treatment of LNCaP, DU145 and MCF-7



12/19

FIG. 10A






FIG. 10B




13/19

FIG. 11




14/19

FIG. 12




15/19

FIG. 13




16/19

FIG. 14



17/19


FIG. 15



18/19

FIG. 16

Cell viability (MTT) curves for Wogonin
Treatment of PTX-10



19/19

FIG. 17

Cell viability (MTT) curves for Isoliquiritigenin
Treatment of PTX-10

